Maia Biotechnology is a public, Texas based, immune-oncology company.
[1] It is led by CEO/Chairman Vlad Vitoc, MD, MBA and Chief Scientific Officer Sergei M. Gryaznov, PhD.
[4] THIO (6-thio-2'-deoxyguanosine) is a drug that attempts to kill cells that express telomerase, which is found in 85% of human cancers.
[1] A phase II THIO-101 clinical trial of THIO sequenced with cemiplimab to treat advanced non-small cell lung cancer (NSCLC).
The study population was patients with advanced NSCLC who did not respond or developed resistance to first-line treatments using another checkpoint inhibitor.